Figure S1. Effect of Met in combination with chemotherapy on apoptosis. (A) Data analysis strategy for determining apoptosis. Analysis of apoptosis of NCI-N87 gastric cancer cells treated with Met in combination with (B) chemotherapy regimens or (C) chemotherapy drugs, as determined by flow cytometry using FITC-Annexin and SYTOX®. Met, metformin; Epi, epirubicin; Cis, cisplatin; Dtx, docetaxel; 5FU, 5-fluorouracil; ECF, epirubicin + cisplatin + 5-fluorouracil; DCF, docetaxel + cisplatin + 5-fluorouracil; CF, cisplatin + 5-fluorouracil.



Figure S2. Data analysis strategy for the determination of caspase activity. (A) First, cells that passed individually (singlets) through the flow cytometer laser were delimited. (B) Then, the cell region was established from singlets. Finally, (C) caspase, (D) caspase-3, (E) caspase-8 and (F) caspase-9 activities were established from the cell region. FSC-H, forward scatter height; FSC-A, forward scatter area; SSC-A, side scatter area.



Figure S3. Effect of Met in combination with chemotherapy regimens. (A) Flow cytometry plots of cells treated with Met alone or in combination with each chemotherapeutic regimen. (B) Percentage of cells in the different phases of the cell cycle (G_0/G_1, S and G_2/M). Data are presented as the mean ± SD from three independent experiments, each performed in triplicate. *P<0.05 vs. control. Met, metformin; ECF, epirubicin + cisplatin + 5-fluorouracil; DCF, docetaxel + cisplatin + 5-fluorouracil; CF, cisplatin + 5-fluorouracil; ns, not significant.